[Seite 177↓]

8. LITERATURVERZEICHNIS

1. Adam R, Bismuth H, Diamond T, Ducot B, Marino M, Astarcioglu I, Johann M, Azoulay D, Chiche L, Bao YM, Catstaing D. Effect of extended cold ischemia with UW solution on graft function after liver transplantation. Lancet 1992; 340: 1373-1376.

2. Andus T, Heinrich PC, Castell JC, Gerok W. Interleukin-6: ein Schlüsselhormon der Akutphase-Reaktion. Dtsch med Wschr 1989; 114: 1710-1716.

3. Aoki N, Yamanaka T. The α2 -antiplasmin inhibitor levels in liver diseases. Clin Chim Acta 1978; 84: 99-105.

4. Allen RD, Zacharski LR, Widirtsky ST. Transformation and motility of human platelets. Details of the shape change and release reaction observed by optical and electron microscopy. J Cell Biol 1979; 83: 126-142.

5. Araki H, Lefer AM. Cytoprotective effect of prostacyclin during hypoxia in the isolated perfused cat liver. Fed Proc 1980; 84: 99-105.

6. Assfalg-Machleidt I, Jochum M, Nast-Kolb D, Siebeck M, Billing A, Joka T, Rothe G, Valet G, Zauner R, Scheuber HP, Machleidt W. Cathepsin B - indicator for the release of lysosomal cysteine proteinases in severe trauma and inflamation. Biol Chem Hoppe-Seyler 1990; 371: 211-222.

7. Astedt B, Lescander I, Ny T. The placental type plasminogen activator inhibitor, PAI-2. Fibrino Thrombol Blood Clott 1987; 1: 203-207.

8. Astrup T. The biological significance of fibrinolysis. Lancet 1956; ii: 565-568.

9. Astrup T, Jespersen J. Thrombosis, disseminated intravascular coagulation and the dynamic haemostatic balance. Aspects of prophylaxis and treatment. Int Angiol 1984; 3: 331-332.

10. Bachmann F. Fibrinolysis. In: Verstraet M, Vermylen J, Lijnen HR, Arnout J (eds.). Thrombosis and haemostasis 1987. Leuven: Leuven University Press, 1987: 227-265.

11. Bakker CM, Knot EAR, Stibbe J, Wilson JHP. Disseminated intravascular coagulation in liver cirrhosis. J Hepatol 1992; 15: 330-335.

12. Bakker CM, Metselaar HJ, Groenland TN, Gomes MJ, Knot EAR, Hesselink EJ, Schalm SW, Stibbe J, Terpestra OT. Increased tissue-type plasminogen activator activity in orthotopic but not in heterotopic liver transplantation: the role of the anhepatic period. Hepatology 1992; 16: 404-408.

13. Bakker CM, Metselaar HJ, Gomes MJ, Porte RJ, Groenland TN, Schalm SW, Terpstra OT, Stibbe J. Intravascular coagulation in liver transplantation. Is it present or not? Thromb Haemostas 1993; 69: 25-28.


[Seite 178↓]

14. Ballard HH, Marcus AJ. Platelet aggregation in portal cirrhosis. Arch Intern Med 1976; 136: 316-319.

15. Barroso Garcia de Silvia E, Gore SM, White DJG, Bourgeon JA, Rolles K, Calne RY. An analysis of risk factors in liver transplantation. Transplant Proc 1986; 18: 1210-1212.

16. Baudo F, DeGasperi A, Redaelli R, Caimi T, Cattaneo D, Mazza E, Corti A, Bellj L, de Cataldo F. AT III replacement therapy in cirrhotic patients undergoing liver transplantation: a randomized study. Thromb Haemostas 1991; 65: 1091 (Abstrakt).

17. Bechstein WO, Riess H, Neuhaus P, Himmelreich G, Steffen R, Slama KJ, Rossaint R, Blumhardt G. The effect of aprotinin on blood product requirements during orthotopic liver transplantation. Clin Transplant 1991; 5: 422-426.

18. Bergström S, Ryhage R, Samuelsson B, Sjövall J. Prostaglandins and related factors. The structures of prostaglandin and E1, F1a, and F1b. J Biol Chem 1963; 238: 2355-2368.

19. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993; 55: 971-976.

20. Biland L, Duckert F, Priesender S, Nyman D. Quantitative estimation of coagulation factors in liver disease: The diagnostic and prognostic value of factor XIII, factor V, and plasminogen. Thromb Haemost 1979; 39: 646-653.

21. Binnema DJ, Dooijewaard G, van Iersel JJL, Turion PNC, Kluft C. The contact-system dependent plasminogen activator from human plasma: identification and characterization. Thromb Haemostas 1990; 64: 390-397.

22. Binnema DJ, van Iersel JJL, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Throm Res 1986; 43: 569-577.

23. Bismuth H, Castaing D, Ericzon BG, Otte JB, Rolles K, Ringe B, Sloof M. Hepatic transplantation in Europe. First report of the European Liver Transplant Registry. Lancet 1987; ii: 674-676.

24. Blecher TE, Terblanche J, Peacock JH. Orthotopic liver transplantation. Coagulation and hematologic changes in the pig. Arch Surg 1968; 96: 331-339.

25. Bloom AL. Intravascular coagulation and the liver. Br J Haematol 1975; 30: 1-7.

26. Böhmig HJ, Fritsch A, Kux M, Lechner G, Lechner K, Reich N, Stockinger L, Zeitelberger P. Gerinnungsveränderungen bei orthotoper Lebertransplantation am Hund. Thromb Diath Haemorrh 1969; 21: 332-345.


[Seite 179↓]

27. Böhmig HJ. The coagulation disorder of orthotopic hepatic transplantation. Semin Thromb Hemostasis 1977; 4: 57-82.

28. Boks AL, Brommer EJP, Schalm SW, van Vliet HHDM. Hemostasis and fibrinolysis in severe liver failure and their relation to hermorrhage. Hepatology 1986; 6: 79-86.

29. Bontempo FA, Lewis JH, van Thiel DH, Spero JA, Ragni MV, Butler P, Israel L, Starzl TE. The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation 1985; 39: 532-536.

30. Booth NA, Anderson JA, Bennett B. Plasminogen activator in alcoholic liver cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol 1984; 37: 772-777.

31. Booth NA, Walker E, Maughan R, Bennett B. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. Blood 1987; 69: 1600-1604.

32. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195.

33. Boylan JF, Klinck JR, Sandler AN, Arellano R, Greig PD, Nierenberg H, Roger SL, Glynn MF. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996; 85: 1043-1048.

34. Brower MS, Levin RI, Garry K. Human neutrophil elastase modulates platelet function by limited proteolysis of membrane glycoproteins. J Clin Invest 1985; 75: 657-666.

35 . Brozovic M. Acquired disorders of coagulation. I: Bloom AL, Thomas DP (eds.). Haemostatis and Thrombosis. Edingburgh: Curchill Livingstone, 1987: 542-553.

36. Bykowska K, Levin EG, Rijken DC, Loskutoff DJ, Collen D. Characterization of a plasminogen activator secreted by cultured bovine aortic endothelial cells. Biochim Biophys Acta 1982; 703: 113-115.

37. Bykowska K, Pawlowka Z, Cierniwski C, Lopaciuk S, Kopec M. Different effects of human neutrophil elastase on platelet glycoproteins IIb and IIIa of resting and stimulated platelets. Thromb Haemostas 1990; 64: 69-73.

38. Caldwell-Kenkel JC, Currin RT, Tanaka Y, Thurman RG, Lemasters JJ. Reperfusion injury to endothelial cells following cold ischemic storage of rat liver. Hepatology 1989; 10: 292-299.

39. Caldwell-Kenkel JC, Currin RT, Tanaka Y, Thurman RG, Lemasters JJ. Kupffer cell activation and endothelial damage after storage of rat livers in Euro-Collins and UW cold storage solutions: effects of reperfusion. Hepatology 1991; 13: 83-95.


[Seite 180↓]

40. Camussi G, Bussolino F, Salvidio G, Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear leukocytes and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med 1987; 166: 1390-1404.

41. Canales J, Gove CD, Gimson AES, Wilkinson SP, Wardle EN, Williams R. Reticuloendothelial system and hepatocyte function in fulminat hepatic failure. Gut 1982; 23: 265-269.

42. Carlson LA, Irion E, Orö L. Effect of infusion of prostaglandin E1 on the aggregation of blood platelets in man. Life Sci 1968; 7(1): 85-90.

43. Castellino EJ. Biochemistry of human plasminogen. Semin Thromb Haemost 1984; 10: 18-23.

44. Cauchie P, Pradier O, Dejonckheere M, Gelin M, Wijns W, Capel P. DIC, Fibrinolysis and aprotinin treatment during orthotopic liver transplantation (OLT). Thromb Haemostas 1991; 65: 1089 (Abstrakt).

45. Cazenave J-P, Gucciono MA, Packham MA, Mustard JF. Effects of cephalothin and penicillin G on platelet function in vitro. Brit J Haematol 1977; 35: 135-152.

46. Charo IF, Feinman RD, Detwiler TC. Interrelations of platelet aggregation and secretion. J Clin Invest 1977; 60: 866-873.

47. Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436.

48. Claeys H, Vermylen J. Purification and characterization of human plasminogen. Physiochemical and proenzyme properties of amine terminal glutamic acid and amino terminal lysine plasminogen. Influence of 6-amino haxanoic acid. Biochim Biophys Acta 1974; 342: 351-359.

49. Clasen C, Jochum M, Mueller-Esterl W. Feasibility study of very high aprotinin dosage in polytrauma patients. In: First Vienna Shock Forum, Part A: Pathophysiological role of mediators and mediator inhibitors in shock . Alan R. Liss. Inc. 1987: 175-183.

50. Clavien P-A, Morgan GR, Sanabria JR, Petruschka C, Levy GA, Robert P, Harvey C, Strasberg SM. Effect of cold preservation on lymphocyte adherence in the perfused rat liver. Transplantation 1991; 52: 412-417.

51. Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med 1986; 414: 1298-1304.

52. Col-De Beys C, Carlier M, Reynaert M, Lavenne-Pardonge E, Legrand-Monsieur A, Otte J-B, Moriau M. Prediction of bleeding during orthotopic liver transplantation in recipients given tranexamic acid. Thromb Haemostas 1991; 65: 1088 (Abstrakt).


[Seite 181↓]

53. Collburn P, Buonassisi V. Anti-clotting activity of endothelial cell and heparan sulfate proteoglycans. Biochem Biophys Res Commun 1982; 104: 220-227.

54. Colletti LM, Burtch GD, Remick DG, Kunkel SL, Strieter RM, Guice KS, Oldham KT, Campell DA. The production of tumor necrosis factor alpha and the developmemt of a pulmonary capillary injury following hepatic ischemia/reperfusion. Transplantation 1990; 49: 268-272.

55. Collen D. Identification and some properties of a new fast reacting plasma inhibitor in human plasma. Eur J Biochem 1976; 69: 209-216.

56. Collen D, Rouvier J, Chamone DAF, Verstraete M. Turnover of radiolabelled plasminogen and prothrombin in cirrhosis of the liver. Eur J Clin Invest 1978; 8: 185-188.

57. Collen, D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89.

58. Colman RW. Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 1969; 35: 273-279.

59. Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semerar N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-1896.

60. Cosimi AB, Geoffrion C, Anderson T, Conti D, Rothlein R, Celvin RB. Immunosuppression of cynomolgers recipients of renal allograft by R66.5, a monoclonal antibody to intercellular adhesion molecule-1. In: Springer TA, Anderson DC, Rosenthal AS, Rothlein RR (eds.). Leukocyte adhesion molecules. New York: Springer, 1990: 274-278.

61. Cotram RS. New roles for the endothelium in inflammation and immunity. Am J Pathol 1987; 129: 407-413.

62. Corrigan JJ. Diagnosis and therapy of coagulopathies in patients with liver disease. In: Brown R (ed.). Anesthesia and the patients with liver disease. Contemporary Anesthesia Practice 4. PA: Davis Comp 1981: 1-11.

63. Cossel L. Electron microscopy of thrombocytes in orthotopic porcine liver homograft during the late rejection (phagocytosis of thrombocytes by Kupffer cells). Virchows Arch A Path Anat Histol 1974; 364: 265-273.

64. Cottam S, Hunt B, Segal H, Ginsburg R, Potter D. Aprotinin inhibits tissue-plasminogen activator mediated fibrinolysis during orthotopic liver transplantation. Transplant Proc 1991; 23: 1933.

65. Cramer EM, Lu H, Caen JP, Soria C, Berndt MC, Tanla D. Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation. Blood 1991; 77: 694-699.


[Seite 182↓]

66. Crutchley DJ, Cananan LB, Maynard JR. Stimulation of fibrinolytic activity in human skin fibroblasts by prostaglandins E1, E2 and I2. J Pharmacol Exp Ther 1982; 222: 544-549.

67. Currin DR, Pechet L. Discriminant analysis on coagulation and fibrinolytic data obtained during liver homotransplantation. Thromb Diath Haemorrh 1969; 22: 411-416.

68. Cywes R, Harvey PR, Packham MA, Cameron R, Strasberg SM. The influence of prostaglandin E1 on platelet adherence and injury in preserved rat liver allografts. Liver Transpl Surg 1996; 2: 23-36.

69. Dahlback B, Stentlo J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sci USA 1981; 78: 2512-2516.

70. Dahlback B. Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S. Biochem J 1983: 209: 847-856.

71. Deutsch E. Blood coagulation changes in liver diseases. In: Popper H, Schaffner F (eds.). Progress in liver disease, Vol. 2, New York, Grune and Stratton 1965: 69-83.

72. Dietrich W, Brankay A, Dilthey G, Henze R, Niekau E, Sebening F, Richter JA. Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application - clinical experience in 152 cardiac surgical patients. Thorac cardiovasc Surgeon 1989; 37: 92-98..

73 . Application to liver transplantation. Surgery 1970; 68: 269-276.

74. Dittmann WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. Blood 1990; 75: 329-336..

75. Dooijewaard G, van Iersel JJL, Brommer EJP. Quantiation of pro-UK, UK, and UK-Inhibitor levels in plasma of patients and healthy men. Fibrinolysis 1987; 1 supp 1: 142 (Abstrakt).

76. Dooijewaard G, de Boer A, Turion PNC, Cohen AF, Breimer DD, Kluft C. Physical exercise induces enhancement of urokinase-type plasminogen activator (u-PA) levels in plasma. Thromb Haemostas 1991; 65: 82-86.

77. Dooijeward G, de Yong YF, Jie AFH, Kluft C. The role of kallikrein in the generation of the factor XII-dependent plasminogen activator activity in human plasma. Thromb Haemost 1985; 54: 268 (Abstakt).

78. Dzik WH, Arkin CF, Jenkins RL, Stump DC. Fibrinolysis during liver transplantation in humans. Role of tissue-type plasminogen activator. Blood 1988; 71: 1090-1095.

79. Edmunds LH, Niewarowski S, Colman RW. Invited letter concerning aprotinin. J Thorac Cardiovasc Surg 1991; 101: 1103-1104.


[Seite 183↓]

80. Emeis JJ. Mechanisms involved in short-term changes in blood levels of t-PA . In: Kluft C (ed.). Tissue-type plasminogen activator (t-PA): physiological and clinical aspects. Boca Raton; CRC press 1988; II: 21-36.

81. Emmons PR, Hampton JR, Harrison MJG, Honour AJ, Mitchell JRA. Effect of prostaglandin E1 on platelet behaviour in vitro and in vivo. Brit Med J 1967; 2: 468-472.

82. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352.

83. Fair DS, Martar RA, Levin EG. Human endothelial cells synthezise protein S. Blood 1986: 67: 1168-1171.

84. Fantone JC, Marasco WA, Elgas LJ, Ward PE. Stimulus specificity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production. Am J Pathol 1984; 115: 9-16.

85. Fickenscher K, Aab A, Stüber W. A photometric assay for blood coagulation factor XIII. Thromb Haemost 1991; 65: 535-540.

86. Finn A, Naik S, Klein N, Levinsky RJ, Strobel S, Elliott M. Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 105: 234-241.

87. Flechter AP, Biederman O, Moore D, Alkjaersig N, Sherry S. Abnormal plasminogen-plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: Its cause and consequences. J Clin Invest 1964; 43: 681-695.

88. Fukami HM, Salganikoff HL. Human platelet storage organelles: A review. Thromb Haemostasis 1977; 38: 963-976.

89. Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin - preliminary results. Thorac Cardiovasc Surgeon 1989; 37: 89-91.

90. Francis RB Jr, Neely S. Inhibition of endothelial secretion of tissue-type plasminogen activator and its rapid inhibitor by agents which increase intracellular cyclic AMP. Biochim Biophys Acta 1989; 1012: 207-213.

91. Fritz H, Jochum M, Duswald KH, Dittmer H, Kortmann H, Neumann S, Lang H. Granulocyte proteinases as mediators of unspecific proteolysis in inflammation: a review. In: Selected Topics in Clinical Enzymology, Vol.2, Goldberg DM, Werner M (eds.). Walter de Gruyter, Berlin-New York, 1984: 306-328.

92. Fritz H, Wunderer G, Jochum M. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneim Forsch/Drug Res 1983; 33: 479-494.


[Seite 184↓]

93. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dietrich MP, Wachter H. Neopterin in clinical medicine (letter). Lancet 1988; 1: 702.

94. Függer R, Hamilton G, Steiniger R, Mirza D, Schulz F, Mühlbacher F. Intraoperative estimation of endotoxin, TNF a , and IL-6 in orthotopic liver transplantation and their relation to rejection and postoperative infection. Transplantation 1991; 52: 302-306.

95. Fuhrer G, Heller W, Hoffmeister H-E. Das Verhalten von Plasma-Präkallikrein/-Kallikrein bei Patienten mit aorto-koronarer Bypass-Operation unter Anwendung zweier verschiedener Aprotinin-Dosierungsschemata. In: Proteolyse und Proteinaseninhibition in der Herz- und Gefäßchirurgie. Dudziak R, Kirchhoff PG, Reuter HD, Schumann F (eds.). Stuttgart: Schattauer Verlag 1985; 255-261.

96. Gaber AO, Thistlethwaite JR Jr, Busse-Henry S, Aboushlove M, Emond J, Rouch D, Broelsch CE. Improved results of preservation of hepatic grafts preflushed with albumin and prostaglandins. Transplant Proc 1988; 20: 992-993.

97. Gans H, Lowman JT. The uptake of fibrin and fibrin degradation products by isolated perfused rat liver. Blood 1967; 29: 526-539.

98. Garcia-Huete L, Domenech P, Sabate A, Martinez-Brotons F, Jaurrieta E, Figueras J. The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation: a randomized clinical study. Hepatology 1997; 26: 1143-1148

99. Geiger M. Protein C Inhibitor/Plasminogen activator inhibitor 3. Fibrinolysis 1988; 2: 183-188.

100. Goldsmith GH, Saito H, Ratnoff OD. The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments. J Clin Invest 1978; 62: 54-60.

101. Goldsmith MF. Liver transplantation: big business in blood. JAMA 1983; 250: 2904-2905.

102. Gonias SL, Pizzo SV. The biochemistry of haemostasis. Clin Lab Haemat 1986; 8: 281-305.

103. Goodpasture EW. Fibrinolysis in chronic hepatic insufficiency. Bull Johns Hopkins Hosp 1914; 25: 330-336.

104. van der Graaf F, Keus FIA, Vlooswijk RAA, Bouma BN. The contact activation mechanism in human plasma: activation induced by dextran sulfate. Blood 1982; 59: 1225-1233.

105. Greig PD, Woolf GM, Sinclair SB, Abecassis M, Strasberg SM, Taylor BR, Blendis LM, Superina RA, Glynn MF, Laner B. Treatment of primary liver graft nonfunction with prostaglandin E1. Transplantation 1989; 48: 447-453.


[Seite 185↓]

106. Groh J, Welte M, Shahnaz CA, Anthuber M, Haller M, Kratzer MAA. Does aprotinin really reduce blood loss in orthotopic liver transplantation? Semin Throm Hemostas 1993; 19: 306-308.

107. Grosse H, Lobbes W, Frambach M, Ringe B, Barthels M. Influence of high-dose aprotinin on hemostasis and blood requirement in orthotopic liver transplantation. Semin Thromb Hemostasis 1993; 19: 302-305.

108. Groth CG, Pechet L, Starzl TE. Coagulation during and after orthotopic transplantation of the human liver. Arch Surg 1969; 98: 31-34.

109. Gubernatis G, Pichelmayr R, Lamesch P, Grosse H, Bornscheuer A, Meyer H-J, Ringe B, Farle M, Bretschneider HJ. HTK-solution (Bretschneider) for human liver transplantation. Langenbecks Arch Chir 1990; 375: 66-70.

110. Gzendlik C, Lammle B, Duckert F. Cold promoted activation and factor VII, prekallikrein and C1-inhibitor. Thrombos Haemostas 1985; 53: 242-244.

111. Haagsma EB, Gips CH, Wesenhagen H, Van Imhoff GW, Krom RAF. Liver disease and its effect on haemostasis during liver transplantation. Liver 1985; 5: 123-128.

112. Hajjar KA, Hajjar DP, Silverstein RL, Nackman RL. Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelial cells. J Exp Med 1987; 16: 235-245.

113. Harpel PC. Plasmin inhibitor interactions: the effectiveness of a 2-antiplasmin inhibitor in the presence of a 2-macroglobulin. J Exp Med 1977; 146: 1033-1040.

114. Harker LA. Bleeding after cardiopulmonary bypass. N Eng J Med 1986; 314: 1446-1448.

115. Harper PL, Luddington RJ, Jennings I, Reardon D, Seaman MJ, Carrell RW, Klinik JR, Smith M, Rolles K, Calne R. Coagulation changes following hepatic revascularisation during liver transplantation. Transplantation 1989; 48: 603-607.

116. Hattey E, Wojta J, Binder BR. Monoclonal antibodies against plasminogen and alpha-2-antiplas binding to native and modified antigens. : Thromb Res 1987; 45: 485-495.

117. Havemann K, Gramse M. Physiology and pathophysiology of neutral proteinases of human granulocytes. In: Hörl WH, Heidland A (eds.). Proteases: Potential role in health and disease. New York, Plenum Publ Corp 1984; 1-13.

118. Himmelreich G, Kierzek B, Riess H. Dextransulfate (DS) stimulated fibrinolytic activity in relation to the activity of tissue plasminogen activator (t-PA) and single and two chain urinary type plasminogen activator ((sc+tc)u-PA). Fibrinolysis 1990; 4: 150-152.


[Seite 186↓]

119. Himmelreich G, Kierzek B, Neuhaus P, Slama KJ, Jochum M, Riess H. Coagulation changes and the influence of the early perfusate in the course of orthotopic liver transplantation (OLT) when aprotinin is used intraoperatively. Blood Coagulation and Fibrinolysis, 1991; 2: 51-59.

120. Himmelreich G, Kierzek B, Neuhaus P, Slama KJ, Riess H. Changes of the fibrinolytic system and the influence of the early perfusate in the course of orthotopic liver transplantation (OLT) when aprotinin is used intraoperatively. Transplant Proc 1991, 23: 1936-1937.

121. Himmelreich G, Riess H. Inhibition of adenosine diphosphate and collagen induced platelet aggregation in vitro by the liver preservation fluid UW solution. Transplant Proc 1991, 23: 1939-1940.

122. Himmelreich G, Riess H. In vitro inhibition of platelet aggregation by the liver preservation fluid UW solution. Transplantation 1991; 52: 30-33.

123. Himmelreich G, Riess H. Die klinische Bedeutung des Fibrinolysesystems. Dtsch med Wschr 1991; 116: 426-430.

124. Himmelreich G, Riess H. Primäre Prophylaxe der venösen Thromboembolie. Die Offizin 1991; 1: 35-38.

125. Himmelreich G, Hundt K, Neuhaus P, Blumhardt G, Riess H. Decreased platelet aggregation after reperfusion in orthotopic liver transplantation. Transplantation 1992; 53: 582-586.

126. Himmelreich G, Muser M, Steffen R, Bechstein WO, Slama KJ, Jochum M, Riess H. Different aprotinin applications influencing hemostatic changes in orthotopic liver transplantation (OLT). Transplantation 1992; 53: 132-136.

127. Himmelreich G, Bechstein WO, Riess H. Aprotinin bei Lebertransplantation. Die gelben Hefte 1992; 32: 166-172.

128. Himmelreich G, Kierzek B, Slama KJ, Riewald M, Neuhaus P, Riess H. Untersuchungen zur Genese der Hämostasestörungen bei orthotoper Lebertransplantation. Landbeck G, Scharrer I, Schramm W (eds.), Springer Verlag 1993 ; 45-48.

129. Himmelreich G, Dooijewaard G, Breinl P, Neuhaus P, Bechstein WO, Kluft C, Riess H. Role of urokinase-type plasminogen activator (u-PA) in orthotopic liver transplantation. Thromb Haemostas 1993; 69: 56-59.

130. Himmelreich G, Hundt K, Neuhaus P, Roissant R, Riess H. Prostaglandin E1 infusion intraoperatively is reducing impaired platelet aggregation after reperfusion in orthotopic liver transplantation. Transplantation 1993; 55: 819-826.


[Seite 187↓]

131. Himmelreich G, Müller C, Isenberg C, Bechstein WO, Roissant R, Riess H. Factor XIII activity during orthotopic liver transplantation. Semin Thromb Hemostasis 1993; 19: 243-245.

132. Himmelreich G, Hundt K, Isenberg C, Bechstein WO, Neuhaus P, Riess H. Thrombocytopenia and platelet dysfunction in orthotopic liver transplantation. Semin Thromb Hemostas 1993; 19: 209-212.

133. Himmelreich G, Hundt K, Bechstein WO, Rossaint R, Neuhaus P, Riess H. Influence of prostaglandin E1 infusion on hemostasis in orthotopic liver transplantation. Semin Thromb Hemostas 1993; 19: 273-278.

134. Himmelreich G, Dooijewaard G, Breinl P, Bechstein WO, Blumhardt G, Kluft C, Riess H. Changes in urokinase-type plasminogen activator in orthotopic liver transplantation. Semin Thromb Hemostas 1993; 19: 311-314.

135. Himmelreich G, Rosch R, Neuhaus P, Riess H. Role of Protein S in orthotopic liver transplantation. Semin Thromb Hemostas 1993; 19: 286-289.

136. Himmelreich G, Riess H. Pathophysiologie und Therapie der Verbrauchskoagulopathie. Klin Lab 1993; 39: 25-30.

137. Himmelreich G, Bechstein WO, Riess H. Aprotinin in liver transplantation. Biomedical Progress 1993; 6: 40-43.

138. Himmelreich G, Riess H, Muser M, Kluft C, Bechstein WO, Riess H, Dooijewaard G. Increased urokinase-type plasminogen activator (u-PA) levels in graft liver perfusate and decreased single chain u-PA activation with higher levels of aprotinin. Thromb Haemostas 1994; 71: 12-14.

139. Himmelreich G, Riewald M, Rosch R, Blumhard G, Neuhaus P, Roissant R, Riess H. Thrombomodulin - a marker of endothelial damage during orthotopic liver transplantation. Am J Hematol 1994; 47: 1-5.

140. Himmelreich G, Rosch R, Neuhaus P, Riess H. Protein S in end stage liver disease and in the course of liver transplantation. Thromb Res 1994; 73: 269-277.

141. Himmelreich G, Jochum M, Machleidt W, Neuhaus P, Riess H. Mediators of leukocyte activation play a role in DIC during orthotopic liver transplantation. Transplantation 1994; 57: 354-358.

142. Himmelreich G, Jochum M, Gippner-Steppert C, Bechstein WO, Riess H. Cytokines and soluble adhesion molecules in orthotopic liver transplantation. Transplantation 2000; (eingereicht).

143. van Hinsberg VWM, van den Berg EA, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 1990; 75: 1991-1998.


[Seite 188↓]

144. Hoffmann MW, Worigeit K, Steinhoff G, Herzbeck H, Flad H-D, Pichlmayr R. Production of cytokines (TNF-alpha, IL-1-beta) and endothelial cell activation in human liver allograft rejection. Transplantation 1993; 55: 329-335.

145. Howland WS, Castro EB, Fortner JB, Gould P. Hypercoaguloability. Thrombelastographic monitoring during extensive hepatic surgery. Arch Surg 1974; 108: 605-608. 605-608.

146. Hutchinson DE, Genton E, Porter KA, Daloze PM, Huguet C, Brettschneider L, Groth CG, Starzl TE. Platelet changes following clinical and experimental hepatic homotransplantation. Arch Surg 1968; 97: 27-33.

147. Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-3489.

148. Ikeda Y, Kikuchi M, Toyama K, Watanabe K, Ando Y. Inhibition of human platelet functions by verapamil. Thromb Haemostas 1981; 45: 158-161.

149. Imagawa DK, Millis JM, Olthoff KM, Derus LJ, Chia D, Sugich LR, Ozawa M, Dempsey RA, Iwaki Y, Levy PJ, Terasaki PI, Busuttil RW. The role of tumor necrosis factor in allograft rejection. Transplantation 1990; 50: 219-225.

150. Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest 1985; 76: 2178-2181.

151. Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood 1986; 67: 362-365.

152. Ishii H, Nakano M, Tsubouchi J, Ishikawa T, Uchiyama H, Hirashi S, Tahara C, Miyajima Y, Kazama M. Establishment of enzyme immunoassay of human thrombomodulin in plasma and urine using monoclonal antibodies. Thromb Haemostas 1990; 63: 157-162.

153. Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618-623.

154. Jamieson NV, Sundberg R, Lindell S, Claesson K, Moen J, Vreugdenhill PK, Wight DGD, Southard JH, Belzer FO. Preservation of the canine liver for 24-48 hours using simple cold storage with UW solution. Transplantation 1988; 46: 517-522.

155. Jespersen J, Kluft C. Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen. Levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator. Thromb Haemostas 1985; 54: 454-459.

56. Jespersen J. The diurnal increase in euglobulin fibrinolytic activity in women using oral contraceptives and in normal women, and the generation of intrinsic fibrinolytic activity. Thromb Haemostas 1986; 56: 186-188.


[Seite 189↓]

157. Jespersen J, Astrup T. A study of the fibrin plate assay of fibrinolytic agents: optimal conditions, reproducibility and precision. Haemostasis 1983; 13: 301-315.

158. Jochum M, Fritz H, Nast-Kolb D, Inthorn D. Granulozyten-Elastase als prognostischer Parameter. Dt Arztebl 1987; 19: 1106-1110.

159. Jochum M. Hämostasefaktoren, Zytokine, leukozytäre Proteasen und lösliche Adhäsionsmoleküle bei Sepsis und Systemic Inflammatory Response Syndrome. Anästhesiologie & Intensivmedizin, 1999; 1(40): 44-49.

160. Jones G, Hurley JV. The effect of prostacyclin on the adhesion of leukocytes to injured vascular endothelium. J Pathol 1984; 142: 51-59.

161. Jorg M, Binder BR. Kinetic analysis of plasminogen activator by purified plasma kallikrein. Thromb Res 1985; 39: 323-331.

162. Juhan-Vague I, Rijken DC, De Cock F, Mandez C, Collen D. Extrinsic plasminogen activator levels in clinical plasma samples. Prog Fibrinolysis 1983; 6: 65-69.

163. Kalayoglu M, Sollinger HW, Stratta RJ, D’Alessandro AM, Hoffmann RM, Pirsch JD, Belzer FO. Extended preservation of the liver for clinical transplantation. Lancet 1988; 1: 617-619.

164. Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BW, Starzl TE, Winter PM. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: 888-896.

165. Kang YG, Lewis JH, Navalgund A, Russell MW, Bontempo FA, Niren LS, Starzl TE. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987; 66: 766-773.

166. Karges HE. Blood coagulation F XIII: Determination by clot stability assays. In: Methods of Enzymatic Analysis. Third Edition, Vol V. Bergmeyer HE (ed.). Verlag Chemie, Weinheim 1984: 400-410.

167. Karmochkine M, Boffa MC, Piette JC, Cacoub P, Wechsler B, Godeau P, Juhan I, Weiller PJ. Increase in plasma thrombomodulin in lupus erythematosus with antiphospholipidantibodies (letter). Blood 1992; 79: 837-838.

168. Kaspar M, Ramsay MA, Nguyen AT, Cogswell M, Hurst G, Ramsay KJ. Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation. Anesth Analg 1997; 85: 281-285.

169. von Kaulla KN. Liver in regulation of fibrinolytic activity. Lancet 1964; i: 1046-1047.


[Seite 190↓]

170. von Kaulla KN, Kayne H, von Kaulla E, Marchioro TL, Starzl TE. Changes in blood coagulation before and after hepatectomy or transplantation in dogs and man. Arch Surg 1966; 92: 71-79.

171. von Kaulla KN. Clotting abnormalities in the host induced by preserved auxiliary lives. Remarks on the regulatory function of kidney and liver in coagulation and fibrinolysis. In: von Kaulla KN (ed.). Coagulation problems in transplanted organs. Springfield, III.: Charles C. Thomas, 1972: 52-64.

172. Kawano T, Morimoto K, Vemura Y. Urokinase inhibitor in human placenta. Nature (Lind.) 1968; 217: 253-254.

173. Kenneth PM, Mentyka RA, Chambers SL, Hugli TE, Herschbach JH, Zuraw BL. Cold-dependent activation of complement: recognition, assessment, and mechanism. J Clin Immunol 1992; 12: 362-370.

174. Kim YJ, Kawano K, Nakashimo K, Gato S, Kobayshi M. Alleviation of 3.5-hour warm ischemic injury of the liver in pigs by cyclosporin pretherapy. Transplantation 1991; 51: 731-733.

175. Kratzer MA, Azad SC, Groh J, Welte M, Haller M, Pratschke E. The effects of aprotinin. Blood loss and coagulation parameters in orthotopic liver transplantation: A clinical-experimental, prospective and randomized double-blind study. Anaesthesist 1997; 46: 294-302.

176. Kelly DA, Tuddenham EGD. Haemostatic problems in liver disease. Gut 1986; 27: 339-349.

177. Kinlough-Rathbone RL, Packham MA, Mustard JF. The effect of prostaglandin E1 on platelet function in vitro and in vivo. Brit J Haematol 1970; 19: 559-571.

178. Kirby RM, McMaster P, Clemens D, Hubscher SG, Angrisani L, Sealey M, Gunson BK, Salt PJ, Buckels JAC, Adams DH, Jurewicz WAJ, Jain AB, Elias E. Orthopic liver transplantation: postoperative complications and their management. Br J Surg 1987; 74: 3-11.

179. Kirchheimer JC, Huber K, Polterauer P, Binder BR. Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma. Thromb Haemostas 1985; 54: 617-618.

180. Kluft C . Levels of plasminogen activators in human plasma: new methods to study the intrinsic and extrinsic activators. In: Davidson JF, Rowen RM, Samama MM, Desnoyers PC (eds.). Progress in chemical fibrinolysis and thrombolysis, Vol.3, New York: Raven Press 1978: 141-164.

181. Kluft C, Trumpi-Kalshoven MM, Jie AFH, Veldhuyzen-Stolk EC. Factor XII-dependent fibrinolysis: a double function of plasma kallikrein and the occurence of a previously undescribed factor XII- and kallikrein-dependent plasminogen proactivator. Throm Haemostas 1979; 41: 756-773.


[Seite 191↓]

182. Kluft C, Trumpi-Kalshoven MM, Jie AFH. Determination of prekallikrein levels in plasma with chromogenic substrates. In: Scully MF, Kakkar VV (eds.). Chromogenic Peptide Substrates: Chemistry and Clinical Usage. Churchill Livingstone, Edinburgh 1979; 84-92.

183. Kluft C. Plasminogen proactivators and activators in human plasma: F XII-dependent fibrinolysis. In Peters H (ed.). Protides of biological fluids. Pergamon Press, Brussels, 1980: 375-378.

184. Kluft C, Wijngaard G, Jie AFH. The factor XII-independent plasminogen proactivator system of plasma includes urokinase-related activity. Thromb Haemost 1981; 46: 343-349.

185. Kluft C, Los P, Svendson L. Blood coagulation factor XII: Hageman factor. In Bergmeyer HV, Bergmeyer J, Grabl M (eds.). Methods of enzymatic analysis, Enzymes 3: Peptidases, proteinases and their inhibitors. Verlag Chemie, Weinheim 1984; 5: 394-399.

186. Kluft C, Wijngaards G, Jie AFH. Intrinsic plasma fibrinolysis: involvement of urokinase-related activity in the factor XII-independent plasminogen proactivator pathway. J Lab Clin Med 1984; 103: 408-419.

187. Kluft C, Doojiewaard G, Emeis JJ. Contact product formation: balanced activation of coagulation and fibrinolysis. In: Schmid-Schonbein H, Wurzinger LJ, Zimmermann RE (eds.). Enzyme Activation in Blood Perfused Artificial Organs. Martinus Nijhoff Publishers, Boston/Dordrecht 1985: 9-31.

188. Kluft C, Doojiewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemostas 1987; 13: 50-68.

189. Kluft C. Pathomechanisms of defective hemostasis during and after extracorporeal circulation: contact phase activation. In: Blood use in cardiac surgery. Friedel N, Hetzer R, Royston D (eds.). Heidelberg: Steinkopff Verlag 1991: 10-15.

190. Knot EAR, Drijfhout HR, ten Cate JW, de Jong E, Iburg AHC, Kahlé LH, Grijm R. a 2-plasmin inhibitor metabolism in patients with liver cirrhosis. J Lab Clin Med 1985; 105: 353-361.

91. Kobayasti H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Günzler WA, Janicke F, Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-u-PA). J Biol Chem 1991; 266: 5147-5152.

192. Kodama S, Uchijima E, Nagai M, Mikawatani K, Hayashi T, Suzuki K. One-step sandwich enzyme immunoassay for soluble thrombomodulin using monoclonal antibodies. Clin Chim Acta 1990; 192: 191-199.

193. Kok P, Nilsson T. Assay characteristics and fibrin affinity of plasminogen activators of the intrinsic fibrinolytic system. Thromb Res 1986; 41: 197-209.


[Seite 192↓]

194. Kraut H, Frey ER, Werle E. Über die Inaktivierung des Kallikreins. Hoppe-Seyler's Z Physiol Chem 1930; 192: 1-21.

195. Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913.

196. Kruithof EKO, Tran-Thang C, Bachmann F. Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemostas 1986; 55: 201-205.

197. Kruithof EKO, Vassalli JD, Schleuning WD, Mattaliono RJ, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell U-937. J Biol Chem 1986; 261: 11207-11213.

198. Kunitz M, Northrop JH. Isolation from beaf pancreas of crystalline trypsinogen, trypsin, trypsin inhibitor, and an inhibitor trypsin compound. J Gem Physiol 1936; 19: 991-1007.

199. Lang H, Fritz H. The role of phagocyte proteinases in the pathobiochemistry of inflammation. In: Advances in Clinical Enzymology. Moss DW, Schmidt E, Schmidt FW (eds.), Karger, Basel, 1986; Vol 3: 168-176.

200. Lang H, Dreher M, Heubner H. Diagnostische Validität der Plasma-Elastase als prädiktiver, biochemischer Marker für infektiöse beziehungsweise entzündliche Komplikationen . Dt Ges f Klin Chemie e.V., Mitteilungen 1, 1989: 10-16.

201. Lang H, Jochum M, Fritz H, Redl H. Validity of the elastase assay in intensive care medicine. In : Schlag G, Redl H (eds.). Second Vienna Shock Forum. Progress in Clinical and Biological Research, Alan R.Liss, Inc. New York; 1989; Vol.308: 701-710.

202. Langley PG, Hughes RD, Williams R. Platelets adhesiveness to glass beads in liver cirrhosis. Acta haemat 1982; 67: 124-127.

203. Larsson LI, Shriver L, Nielsen LS, Grondahl-Hansen J, Kristensen P, Dano K. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Biol Chem 1984; 98: 894-903.

204. Lechner K, Fritsch A, Mach K, Beneckendorff P, Reich N, Kux M, Boehmig HJ. Intravascular coagulation in orthotopic transplantation of the canine liver . In: von Kaulla KN (ed.). Coagulation problems in transplanted organs. Springfield, III., Charles C. Thomas , 1972: 5-15.

205. Levy LR, Lepow IH. Assay and properties of serum inhibitor of C1-esterase. Proc Soc Exp Biol Med 1959; 101: 608-611.

206. Lewis JH, Doyle AP. Effects on epsilon amino caproic acid on coagulation and fibrinolytic mechanisms. J Am Med Ass 1964; 188: 56-63.


[Seite 193↓]

207. Lewis JH, Bontempo FA, Kang YG, Spero JA, Ragni MV, Starzl TE. Intraoperative coagulation changes in liver transplantation. In: Winter PM, Kang YG (eds.). Hepatic transplantation . Praeger, New York, 1986: 142-150.

208. Lewis JH, Bontempo FA, Cornela FW, Kiss JE, Larson P, Ragni MV, Rice EO, Spero JA, Starzl TE. Blood use in liver transplantation. Transfusion 1987; 27: 222-225.

209. Lewis JH, Bontempo FA, Kang YG, Kiss JE, Ragni MV, Spero JA, Starzl TE. Liver transplantation: intraoperative changes in coagulation factors in 100 first transplants. Hepatology 1989; 9 : 710-714.

210. Lie TS, Seger R, Hong GS, Preissinger H, Ogawa K. Protective effect of aprotinin on ischemic hepatocellular damage. Transplantation 1989; 48: 396-399.

211. Lijnen HR, Zamarron C, Blaber M, Winkler ME, Collen D. Activation of plasminogen by pro-urokinase. J Biol Chem 1986; 261: 1253-1258.

212. Llamas P, Cabrera R, Gomez-Arnau J, Fernandez MN. Hemostasis and blood requirements in orthotopic liver transplantation with and without high-dose aprotinin. Haematologica 1998; 83: 338-346.

213. Lohse W, Winkler H, Wolff H. Zur Bedeutung des Antithrombin III bei der klinischen Lebertransplantation. Zentralbl Chir 1985; 110: 803-810.

214. Lorand L, Losowsky MS, Miloszewski KJM. Human factor XIII: Fibrin-stabilizing factor. Prog Haemost Thromb 1980; 5: 245-251.

215. Loskutoff DJ, Mussoni L. Interaction between fibrin and the plasminogen activator produced by cultured endothelial cells. Blood 1983; 62: 62-68.

216. Lu H, Soria C, Cramer EM, Soria J, Maclowf J, Perrot JI, Li H, Commin PL, Schumann F, Regnier O, Lijnen RH, Caen JP. Temperature dependence of plasmin-induced activation or inhibition of human platelets. Blood 1991; 77: 996-1005.

217. Luscinskas FN, Cybursky MI, Keily JM, Perkins CS, Davis VM, Gimbrone Jr MA. Cytokine-activated human endothelial monolayers support enhanced neutrophil transmigration via a mechanism involving both endothelial-leukocyte adhesion- and intercellular adhesion molecule-1. J Immunol 1991; 146: 1617-1625.

218. Machovich R, Himer A, Owen WG. Neutrophil proteases in plasminogen activation. Blood Coagulation and Fibrinolysis, 1990; 1: 273-277.

219. Machovich R, Owen WG. An elastase-dependent pathway of plasminogen activation. Biochemistry 1989; 28: 4517-4522.


[Seite 194↓]

220. Maddrey WC, van Thiel DH. Liver transplantation: an overview. Hepatology 1988; 8: 948-959.

221. Mallett SV, Cox D, Burroughs AK, Rolles K. The intraoperative use of trasylol (aprotinin) in liver transplantation. Transplant Int 1991; 4: 227-230.

222. Mahmoud M, Gaffney PJ. Bioimmunoassay (BIA) of tissue plasminogen activator (t-PA) and its specific inhibitor (t-PA/INH). Thromb Haemostas 1985; 53: 356-359.

223. Mannucci PM, Forman SP. Hemostasis and thrombosis. In: Colman RW, Hirsh J, Marder VJ (eds.). Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott, 1982: 595-601.

224. Marcel RJ, Stegall WC, Suit CT, Arnold JC, Vera RL, Ramsay MA, O’Donnell MB, Swygert TH, Hein HA, Whitten CW. Continuous small-dose aprotinin contro^^ls fibrinolysis during orthotopic liver transplantation. Anesth Analg 1996; 82: 1122-1125.

225. Martinez J, Palascak JE. Hemostatic alterations in liver disease. In : Zakim D, Boyer JA (eds.). Hepatology. Phil Saunders 1982: 546-582.

226. Martinez J, Iglewicz B. A test for departure from normality based on biweight estimator of scale. Biometrika 1981; 68: 331-335.

227. Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 1985; 101: 363-371.

228. Mathews KP, Mentyka RA, Chambers SL, Hugli TE, Herschbach JH, Zuraw BL . Cold-dependent activation of complement: recognition, assessment, and mechanism. J Clin Immunol 1992; 12: 362-370.

229 . McDonagh J. Structure and function of factor XIII in hemostasis and thrombosis. In: RW Colman, J Hirsh, VJ Marder, EW Salzman (eds.). Hemostasis and thrombosis . Lippincott, Phiadelphia, 1987: 289-300.

230. Miles LA, Greengad JS, Griffin JH. A comparison of the abilities of plasma kallikrein, ß-factor XIIa, factor XIa and urokinase to activate plasminogen. Thromb Res 1983; 29: 407-414.

231. Monden H, Fortner JG. Twenty-four and 48-hour canine liver preservation by simple hypothermia with prostacyclin. Ann Surg 1982; 196: 38-42.

232. Morgan GR, Harvey PRC, Strasberg SM. Aprotinin for the pretreatment of liver allograft donors (letter) Transplantation 1990; 49: 1203.


[Seite 195↓]

233. Moriau M, Kestens PJ, Masure R. Heparin and antifibrinolytic agents during experimental hepatectomy and liver transplantation. Pathol Eur 1969; 4: 172-182.

234. Moriau M, Kestens PJ, Otte JB, Masure R. Hemostatic changes during hepatectomy, orthotopic liver transplantation, and graft rejection: an experimental and clinical study. In: von Kaulla KN (ed.). Coagulation problems in transplanted organs. Springfield, III: Charles C, Thomas, 1972: 16-23.

235. Morishita E, Saito M, Asakura H, Jokaji H, Uotani C, Kumabashiri I, Yamazaki M, Matsuda T. Increased levels of plasma thrombomodulin in chronic myelogenous leukemia. Am J Hematol 1992; 39: 183-187.

236. Moroi M, Aoki N. Isolation and characterization of a 2-plasmin inhibitor from human plasma. J Biol Chem 1976; 251: 5956-5965.

237. Motschman TL, Tawell HF, Brecher ME, Rakelo J, Grambsch PM, Larson-Keller JJ, Rettke SR, Krom RAF. Intraoperative blood loss and patient and graft survival in orthotopic liver transplantation: their relationship to clinical and laboratory data. Mayo Clin Proc 1989; 64: 346-355.

238. Motschman TL, Taswell HF, Brecher ME, Rettke SR, Weismer RH, Krom RAF. Blood bank support of liver transplantation program. Mayo Clin Proc 1989; 64: 103-111.

239. von Müller C, Fleischer J, Renger F, Wolff H. Das Gerinnungssystem bei Leberkrankheiten unter besonderer Berücksichtigung der Lebertransplantation. Z Gesamte Inn Med 1981; 36: 660-665.

240. Müller-Berghaus G, Reuter C, Bleyl U. Experimental galactosamine-induced hepatitis. Am J Pathol 1976; 82: 393-404.

241. Müller-Berghaus G, Preissner KT. Regulation der Thrombinaktivität an der Interphase zwischen Blut und Gefäßwand, Interaktion der Komponenten Protein C, Protein S und Thrombomodulin. Hämostaseologie 1987; 7: 14-23.

242. Müller-Esterl W, Oettl A, Truscheit E, Fritz H. Monitoring of aprotinin plasma levels by an enzyme-linked immunosorbent assay (ELISA). Fresenius Z Anal Chem 1984; 317: 718.

243. Müllertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976; 159: 545-553.

244. Mulvin D, Jones K, Howard R, Grosso M, Repine J. The effect of prostacyclin as a constituent of a preservation solution in protecting lungs from ischemic injury because of its vasodilatory properties. Transplantation 1990; 49: 828-830.


[Seite 196↓]

245. Munkvad S, Jespersen J, Gram J, Kluft C. Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study. J Am Coll Cardiol 1991; 17: 957-962.

246. Munkvad S, Jespersen J, Gram J, Kluft C. Depression of factor XII-dependent fibrinolytic activity characterizes patients with early myocardial reinfarction after recombinant tissue-type plasminogen activator therapy. J Am Coll Cardiol 1991; 18: 454-458.

247. National Institutes of Health consensus development conference statement: liver transplantation. Hepatology 1984; 4: 1078-1108.

248. Nawroth PP, Stern DM. Modulation of endothelial-cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745.

249. Neuhaus P, Bechstein WO, Hopf U, Blumhardt G, Steffen R. Indikationen und aktuelle Entwicklung der Lebertransplantation. Leber Magen Darm 1989; 19: 289-308.

250. Neuhaus P, Blumhardt G, Bechstein WO, Steffen R, Keck H. Side-to-side anastomosis of the common bile duct is the method of choice for biliary tract reconstruction after liver transplantation. Transplant Proc 1990; 22: 1571.

251. Neuhaus P, Bechstein WO, Lefèbre B, Blumhardt G, Slama K. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet 1988; II: 1924.

252. Neumann S, Gunzer G, Hennrich N, Lang H. PMN elastase assay: Enzyme immunoassay for human polymorphonuclear elastase complexed with alpha1-proteinase inhibitor. J Clin Chem Clin Biochem 1984; 22: 693-697.

253. Nichol CA, Smith GK, Duch DS. Biosynthesis and metabolism of tetrahydrobiopterin and molybdoperin. Ann Rev Biochem 1985; 54: 729-764.

254. Nicolini FA, Wilson AC, Mento P, Mehto JL. Comparative platelet inhibitory effects of human neutrophils and lymphocytes. J Lab Clin 1990; 116: 147-152.

255. Nilsson IM, Sjoerdsma A, Waldenstrom J. Antifibrinolytic activity and metabolism of epsilon amino caproic acid in man. Lancet 1960; i: 1322-1326.

256. O'Connell RA, Grossi CE, Rousselot LM. Role of inhibitors of fibrinolysis in hepatic cirrhosis. Lancet 1964; ii: 990-991.

257. Oehler G, Bleyl H, Bischoff B, Henk R. Vergleich von Prothrombin-Aktivität und -Konzentration bei verschiedenen Funktionszuständen der Leber. Verh dtsch Ges inn Med 1974: 80; 1452-1456.


[Seite 197↓]

258. Ohno N, Ichikawa H, Coe L, Kvietys PR, Grander DN, Alexander JS. Soluble selectins and ICAM-1 modulate neutrophil-endothelial adhesion and diapedesis in vitro. Inflammation 1997; 21: 313-324.

259. Olthoff KM, Millis JM, Imagawa DK, Nuesse BJ, Derus LJ, Rosenthal JT, Milewicz AL, Busuttil RW. Comparison of UW solution and Euro-Collins solutions for cold preservation of human liver grafts. Transplantation 1990; 49: 284-290.

260. Ossanna PJ, Test ST, Matheson NR, Regiani S, Weiss SJ. Oxidative regulation of neutrophil elastase - a 1-proteinase inhibitor interactions. J Clin Invest 1986; 77: 1939-1951.

261. Otto G, Wolff H, Uerlings I, Gellert K. Preservation damage in liver transplantation. Influence of rapid cooling. Transplantation 1986; 42: 122-124.

262. Owen CA, Rettke SR, Bowie EJW, Cole TL, Jensen CC, Wiesner RH, Krom RAF. Hemostatic evaluation of patients undergoing liver transplantation. Mayo Clin Proc 1987; 62: 761-772.

263. Palareti G, De Rosa V, Fortunato G, Grauso F, Legnani C, Maccaferri M, Poggi M, Bianchini B, Bellusci R, Franceschelli N, Coccheri S. Control of hemostasis during orthotopic liver transplantation. Fibrinolysis 1988; 2, suppl 3: 61-66.

264. Patrassi GM, Viero M, Sartori MT, De Silvestro G, Rossaro L, Burra P, Nolli ML, Piccinni P, Bassi N. Aprotinin efficacy on intraoperative bleeding and transfusion requirements in orthotopic liver transplantation. Transfusion 1994; 34: 507-511.

265. Pechet L, Groth CG, Daloze PM. Changes in coagulation and fibrinolysis after orthotopic canine liver homotransplantation. J Lab Clin Med 1968; 73: 91-102.

266. Perkins HA, May RE, Belzer FO. Cause of abnormal bleeding after transplantation of pig liver stored by a perfusion technique. Arch Surg 1970; 101: 62-68.

267. Plevak DF, Halma GA, Forstrom LA, Dewanjee MK, O'Connor MK, Moore SB, Krom RAF, Rettke SR. Thrombocytopenia after liver transplantation. Transplant Proc 1988; XX,suppl 1 630-633

268. Pober JS, Gimbrone MA, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, Springer TA. Overlapping patterns of activation of human endothelial cells by interleuki 1, tumor necrosis factor and immune interferon. n J Immunol 1986; 137: 1893-1896.

269. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation 1990; 50: 537-544.

270. Poller L. Coagulation abnormalities in liver disease. In: Poller L (ed.). Recent advances in blood coagulation. Edinburgh: Churchill Livingstone, 1977: 267-292.


[Seite 198↓]

271. van der Poll T, van Deventer SJH, Hack CE, Wolbink GJ, Aarden LA, Büller HR, ten Cate JW. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 1992; 79: 693-698.

272. Popov S, Kalinkel H, Etzel F, Bayman E, Egli H. Coagulation changes during and after liver transplantation in man. In: von Kaulla KN (ed.). Coagulation problems in transplanted organs. Springfield, III.: Charles C. Thomas, 1972: 31-51.

273. Porte RJ, Blauw E, Knot EAR, de Maat MPM, de Ruitter C, Terpstra OT. Role of the donor liver in the origin of thrombocytopenia and hemostatic disorder in porcine liver transplantation. In: Porte RJ: Hemostatic disorders in orthotopic and auxiliary liver transplantation. Clinical and experimental studies (thesis). Erasmus University, Rotterdam, The Netherlands 1989: 37-54.

274. Porte RJ, Knot EAR, Bontempo FA. Hemostasis in liver transplantation: a review gastroenterology 1989; 97: 488-501.

275. Porte RJ, Bontempo FA, Knot EAR, Lewis JH, Kang YG, Starzl TE. Systemic effects of tissue plasminogen activator associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989; 47: 978-985.

276. Porte RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, Palareti G, Hermans J, Terpstra OT. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicenter randomised double-blind study EMSALT Study Group . Lancet 2000; 355: 1303-1309.

277. Powers JC, Harper JW. Serine protease inhibitors. In: Barrett AJ, Salveson G (eds.). Proteinase inhibitors. Elsevier Science Publishers BV, Amsterdam 1986: 55-152.

278. Rake MO, Flute PT, Pannell G, Shilkin KB, Williams R. Experimental hepatic necrosis: studies on coagulation abnormalities, plasma clearance, and organ distribution of 125 I-labelled fibrinogen. Gut 1973; 14: 574-580.

279. Ratnoff OD. Disordered haemostasis in hepatic disease . In: Schiff L, Schiff ER (eds.). Disease of the liver. New York: Lippincott, 1987: 187-207.

280. Reganon E, Vila V, Aznar J, Garrido G, Estelles A, Berenguer J. Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia. Thromb Res 1987; 46: 705-714.

281. Richards EM, Alexander GJ, Calne RY, Baglin TP. Thrombocytopenia following liver transplantation is associated with platelet consumption and thrombin generation. Br J Haematol 1997; 98: 315-321.


[Seite 199↓]

282. Riess H, Jochum M, Machleidt W, Himmelreich G, Slama KJ, Steffen R. Possible role of the phagocytic proteinases cathepsin B and elastase in orthotopic liver transplantation. Transplant Proc 1991; 23: 1947-1948.

283. Riess H, Jochum M, Machleidt W, Himmelreich G, Blumhardt G, Roissant R, Neuhaus P. Possible role of extracellularly released phagocyte proteinases in the coagulation disorder during liver transplantation. Transplantation 1991, 52: 482-490.

284. Riess H, Jochum M, Machleidt W, Himmelreich G, Bechstein WO, Muser M, Neuhaus P, Roissant R, Huhn D. Role of leukocytes in hemostasis during orthotopic liver transplantation. Semin Thromb Hemostas 1993; 19: 197-208.

285. Riess H, Himmelreich G, Jochum M, Machleidt W, Hundt K, Neuhaus P, Huhn D. Hemostasis in orthotopic liver transplantation - a model for studying DIC developement? In: DIC - pathogenesis, diagnosis and therapy of disseminated intravascular fibrin formation. G Müller-Berghaus, K Madleiner, M Blombäck, JW ten Cate (eds.). Excerpta Medica Amsterdam 1993: 71-81.

286. Rijken DC, Binnema DJ, Los P. Specific fibrinolytic properties of different molecular forms of pro-urokinase from a monkey kidney culture. Thromb Res 1986; 42: 761-768.

287. Rö JS. Hemostatic problems in liver surgery. Scand J Gastroenterol 1973; 8(Suppl 1): 71-81.

288. Roberts HR, Cederbaum AI. The liver and blood coagulation: physiology and pathology. Gastroenterology 1972; 63: 297-320.

289. Royston D, Bidstrup BP, Taylor IZM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open heart surgery. Lancet 1987; ii: 1289-1291.

290. Salat A, Mueller MR, Boehm D, Stangl P, Pulaki S, Laengle F. Influence of UW solution on in vitro platelet aggregability. Transpl Int 1996; 9: S429-S431.

291. Sato M, Nashan B, Ringe B, Grosse H, Barthels M, Pichelmayr R. Coagulation disorders during liver transplantation. Blood Coagulation and Fibrinolysis 1991; 2: 25-31.

292. Schapiro M, de Agostini A, Colman RW. C1-inhibitor: The predominant inhibitor of plasma kallikrein. Meth Enzymol 1988; 163: 179-185.

293. Schiller JH, Witt PL, Storer B, Alberti D, Tombes MB, Arzoomanium R, Brown RR, Dractor RA, Voss SD, Springs DR, Trump DL, Borden EC. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. Cancer 1992; 69: 562-571.

294. Seekamp A, Jochum M, Ziegler M, van Griensven M, Martin M, Regel G. Cytokines and adhesion molecules in elective and accidental trauma-related ischemia/reperfusion. J Trauma Injury Infec Crit Care 1998: 44: 874-882.


[Seite 200↓]

295. Scudamore CH, Randall TE, Jewesson PJ, Shackleton CR, Salvian AJ, Fagan M, Frighetto L, Growe GH, Scarth I, Erb SR. Aprotinin reduces the need for blood products during liver transplantation. Am J Surg 1995; 169: 546-549.

296. Segal HC, Hunt BJ, Cottam S, Beard C, Francis JL, Potter D, Tan KC. Changes in the contact system during orthotopic liver transplantation with and without aprotinin. Transplantation 1995; 59: 366-370.

297. Segal H, Cottam S, Potter D, Hunt BJ. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997; 25: 683-688.

298. Shattil SJ, Bennett JS, McDonough M, Turnball J. Carbenicillin and Penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J Clin Invest 1980; 65: 329-337.

299. Shaw BW, Martin DJ, Marquez JM, Kang YG, Bugbee AC, Iwatsuki S, Griffith BP, Hardesty RL, Bahnson HT, Starzl TE. Venous bypass in clincal liver transplantation. Ann Surg 1984; 200: 524-534.

300. Silverman P, Goldsmith GH, Spitzer TR, Rehmus EH, Berger NA. Effect of tumor necrosis factor on the human fibrinolytic system. J Clin Oncology 1990; 8: 468-475.

301. Sinclair SB, Greig PD, Blendis LM, Woolf GM, Abecassis M, Strassberg SM, Levy GA. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E1. A preliminary report. J Clin Invest 1989; 84: 1063-1069.

302. Sinzinger H, Virgolini I, Fitscha P, Rauscha F, Kaliman J. Stabilization of endothelial lining and decrease in circulating endothelial cells - one mechanism underlying the clinical action of PGE1? Br J Clin Pharmacol 1988; 25: 775-776.

303. Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC. Cooperative interactions of LFA-1 and MAL-1 with intercellular adhesion molecule-1 infacilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest 1989; 83: 2008-2017.

304. Smith O, Hazlehurst G, Brozovic B, Rolles K, Burroughs A, Mallett S, Dawson K, Mehta A. Impact of aprotinin on blood transfusion requirements in liver transplantation. Transfus Med 1993; 3: 97-102.

305. Spaet TH, Horowitz HI, Franklin DZ, Cintron J, Biezensi JJ. Reticuloendothelial clearance of blood thromboplastin in rats. Blood 1961; 17: 196-205.

306. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387.


[Seite 201↓]

307. Starzl TE, Marchioro TL, von Kaulla KN, Herrman G. Homotransplantation of the liver in humans. Surg Gynecol Obst 1963; 117: 659-676.

308. Starzl TE, Iwatsuki S, van Thiel DH, Gartner JC, Zitelli BJ, Malatack JJ, Schade RR, Shaw BW, Hakala TR, Rosenthal HJT, Porter KA. Evolution of liver transplantation. Hepatology 1982; 2: 614-636.

309. Starzl TE, Demetris AJ, van Thiel DH. Liver transplantation. N Engl J Med 1984; 311: 1658-1664.

310. Starzl TE, Demetris AJ, van Thiel DH. Liver transplantation (first of two parts). N Engl J Med 1989; 321: 1014-1022.

311. Stein SF, Harker LA. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patientes with hepatic cirrhosis. J Lab Clin Med 1982; 99: 217-230.

312. Stern D, Brett J, Harris K, Nawroth P. Participation of endothelial cells in the protein C-protein S anticoagulant pathway: the synthesis and release of protein S. J Cell biol 1986; 102: 1971-1978.

313. Stremple JF, Hussey CV, Ellison EH. Study of clotting factors in liver transplantation. Am J Surg 1966; 111: 862-869.

314. Sumimoto R, Jamieson NV, Wake K, Kamada N. 24-hour rat liver preservation using UW solution and simplified variants. Transplantation 1989; 48: 1-5.

315. Stump DC, Lijnen HR, Collen D. Purification and characterization of single-chain urokinase type activator from human cell cultures. J Biol Chem 1986; 261: 1274-1278.

316. Suzuki K, Nichioka J, Hayaoni T, Kosaka Y. Functionally active thrombomodulin is present in human platelets. J Biochem 1988; 104: 628-632.

317. Takahashi H, Hanano M, Wada K, Tatewaki W, Niwano H, Tsubouchi J, Nakano M, Nakamura T, Shibata A. Circulating thrombomodulin in thrombotic thrombocytopenic purpura. Am J Hematol 1991; 38: 174-177.

318. Takahashi H, Ito S, Hanano M, Wada K, Niwano H, Seki Y, Shibata A. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol 1992; 41: 32-39.

319. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-2029.

320. Takei Y, Marzi I, Gao W, Gores GJ, Lemasters JJ, Thurman RG. Leukocyte adhesion and cell death following orthotopic liver transplantation in the rat. Transplantation 1991; 51: 959-965.


[Seite 202↓]

321. Tanaka A, Ishii H, Hiraishi S, Kazama M, Maezawa H. Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 1991; 37: 269-272.

322. Tankersley DL, Finlayson JS. Kinetics of activation and autoactivation of human factor XII. Biochemistry 1984; 23: 273-279.

323 T . ate KM, Higgins DL, Holmes WE, Winkler ME, Heyneker HL, Vehar GH. Functional role of proteolytic cleavage at arginine - 275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. J Biochem 1987; 26: 338-343.

324. Taylor KM. Aprotinin therapy in cardiac surgery. Therapy Express 1991; 37: 1-5.

325. Thorsen S. Difference in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of aminocarboxylic acids. Biochim Biophys Acta 1975; 393: 55-65.

326. van Thiel DH, Tarter R, Gavaler JS, Potanka WM, Schade RR. Liver transplantation in adults. An analysis of cost and benefits at the University of Pittsburgh. Gastroenterology 1986; 90: 211-216.

327. Tilsner V. Aktivierung der endogenen Fibrinolyse durch Prostaglandin E1. In: Heidrich H, Böhme H, Rogatti W (eds.). Prostaglandin E1 Wirkungen und therapeutische Wirksamkeit. Springer-Verlag, Berlin, Heidelberg 1988: 76-79.

328. Todo S, Tzakis A, Starzl TE. Preservation of livers with UW or Euro-Collins solution. Transplantation 1988; 46: 925-926.

329. Todo S, Nery J, Katsuhiko Y, Podesta L, Gordon RD, Starzl TE. Extended preservation of human liver grafts with UW solution. JAMA 1989; 261: 711-714.

330. Toghill PJ, Green S, Ferguson R. Platelet dynamics in chronic liver disease with special reference to the role of the spleen. J Clin Pathol 1977; 30: 367-371.

331. Tranquille N, Emeis JJ. Release of tissue-type plasminogen activator is induced in rats by leukotrienes C4 and D4, but not by prostaglandins E1, E2 and I2. Br J Pharmacol 1988; 93: 156-164.

332. Troppmair J, Nachbaur K, Herold M, Aulitzky W, Tilg H, Gastl G, Bieling P, Kotlan B, Flener R, Mull B, Aulitzky WO, Rokos H, Huber C. In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharide (LPS). Clin Exp Immunol 1988; 74: 392-397.

333. Thurman RG, Marzi I, Seitz J, Lemasters JJ, Zimmermann FA. Hepatic reperfusion injury following orthotopic liver transplantation in the rat. Transplantation 1988; 46: 502-506.


[Seite 203↓]

334. Tygat GN, Collen D, Verstraete M. Metabolism of fibrinogen in cirrhosis of the liver. J Clin Invest 1971; 50: 1690-1701.

335. Vaughan DE, Plavin SR, Schafer AI, Loscalzo J. PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood 1989; 73: 1213-1217.

336. Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269.

337. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurence of a fast acting inhibitor of tissue type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395.

338. Verstraete M, Vermylen J, Collen D. Intravascular coagulation in liver disease. Ann Rev Med 1974; 25: 447-455.

339. Verstraete M. Clinical applications of inhibitors of fibrinolysis. Drugs 1985; 29: 236-261.

340. Verstraete M, Su CAPF, Transwell P, Feuerer W, Collen D. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. Thromb Haemostas 1986; 56: 1-5.

341. Wachtfogel YT, Harpel PC, Edmunds LH, Colman RW. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin- a 2-plasmin inhibitor complexes during cardiopulmonary bypass. Blood 1991; 73: 468-471.

343. Wada H, Ohiwa M, Kaneko T, Tamaki S, Tanigawa M, Shirakawa S, Koyama M, Hayashi T, Suzuki K. Plasma thrombomodulin as a marker of vascular disorders in thrombotic-thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 1992; 39: 20-24.

344. Wahlberg J, Southard JH, Belzer FO. Development of a cold storage solution for pancreas preservation. Cryobiology 1986; 23: 477-482.

345. Walsh PN. The role of platelets in the contact phase of blood coagulation. Brit J Haemat 1972; 22: 237-254.

346. Walsh PN. The effects of collagen and kaolin in the intrinsic coagulant activity of platelets. Evidence for an alternative pathway in intrinsic coagulation not requiring factor XII. Brit J Haemat 1972; 22: 393-405.

347. Wanaka K, Okamoto S, Bohgaki M, Hijikata-Okunomiya A, Naito T, Okada Y. Effect of a highly selective plasma-kallikrein synthetic inhibitor on contact activation relating to kinin generation, coagulation and fibrinolysis. Thromb Res 1990; 57: 889-895.


[Seite 204↓]

348. Wasantapruek S, Homates J, von Kaulla KN, Eisenmann B. Clotting abnormalities including intravascular coagulation following transplantation of preserved livers in pigs. Thromb Diath Haemorrh 1969; 36(Suppl): 319-332.

349. Weiner M, de Crinis K, Redisch W, Steele JM. Influence of some vasoactive drugs on fibrinolytic activity. Circulation 1959; 19: 845-848.

350. Weksler BB, Ley CW, Jaffe EA. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin and the ionophore A 23187. J Clin Invest 1978; 62: 923-930.

351. Wenger RK, Lukasiewicz H, Mikuta BS, Niewkarowski S, Edmunds LH. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989; 97: 235-239.

352. Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993; 55: 1033-1041.

353. Westlin WF, Gimbrone MA. Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation. Am J Pathol 1993; 142: 117-128.

354. Wijngaards G, Kluft C, Groeneveld E. Demonstration of urokinase-related fibrinolytic activity in human plasma. Br J Haematol 1982; 51: 165-169.

355. Wildevuur CRH, Eijsman L, Roozendaal KJ, Harder MP, Chang M, van Oeven W. Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg 1989; 3: 533-538.

356. Wiman B, Collen D. On the mechanism of the reaction between human a 2-antiplasmin and plasmin. J Biol Chem 1979; 254: 9291-9297.

357. Wolpl A, Lattke H, Board PG, Arnold R, Schmeiser T, Kubanek B, Robin-Winn M, Pichelmayr R, Goldmann SF. Coagulation factor XIII A and B subunits in bone marrow and liver transplantation. Transplantation 1987; 43: 151-153.

358. Wurzel HA. Incidence of various coagulation defects and their association with different diseases. Am J Med Sci 1961; 241: 625-631.

359. Zurborn K-H, Gram J, Rohwedder E, Bewig B, Bruhn HD. Der Einfluss der Leberzirrhose auf die Aktivierung des Gerinnungs- und Fibrinolysesystems und auf die Gerinnungsinhibitoren. Med Klin 1989; 84: 515-518.

360. Zurborn K-H, Kirch W, Bruhn HD. Immunological and functional determination of the protease inhibitors, protein C and antithrombin III in liver cirrhosis and in neoplasia. Thrombos Res 1988; 52: 325-336.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
15.09.2004